Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jul;26(3):604-30.
doi: 10.1128/CMR.00016-13.

Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories

Affiliations
Review

Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories

Carey-Ann D Burnham et al. Clin Microbiol Rev. 2013 Jul.

Abstract

Clostridium difficile is a formidable nosocomial and community-acquired pathogen, causing clinical presentations ranging from asymptomatic colonization to self-limiting diarrhea to toxic megacolon and fulminant colitis. Since the early 2000s, the incidence of C. difficile disease has increased dramatically, and this is thought to be due to the emergence of new strain types. For many years, the mainstay of C. difficile disease diagnosis was enzyme immunoassays for detection of the C. difficile toxin(s), although it is now generally accepted that these assays lack sensitivity. A number of molecular assays are commercially available for the detection of C. difficile. This review covers the history and biology of C. difficile and provides an in-depth discussion of the laboratory methods used for the diagnosis of C. difficile infection (CDI). In addition, strain typing methods for C. difficile and the evolving epidemiology of colonization and infection with this organism are discussed. Finally, considerations for diagnosing C. difficile disease in special patient populations, such as children, oncology patients, transplant patients, and patients with inflammatory bowel disease, are described. As detection of C. difficile in clinical specimens does not always equate with disease, the diagnosis of C. difficile infection continues to be a challenge for both laboratories and clinicians.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Prevalence of C. difficile ribotypes in England, 2007 to 2011. Data are stratified by quarter. (Reproduced from reference with permission from Public Health England.)
None
None

References

    1. Voth DE, Ballard JD.2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18:247–263 - PMC - PubMed
    1. Figueroa I, Johnson S, Sambol SP, Goldstein EJ, Citron DM, Gerding DN. 2012. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin. Infect. Dis. 55(Suppl 2):S104–S109.10.1093/cid/cis357 - DOI - PMC - PubMed
    1. Hall IC, O'Toole E.1935. Intestinal flora in newborn infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am. J. Dis. Child. 49:390–402
    1. Bartlett JG.2009. Clostridium difficile infection: historic review. Anaerobe 15:227–229 - PubMed
    1. Synder MD.1937. Further studies on Bacillus difficilis. J. Infect. Dis. 60:223

Publication types

MeSH terms